- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00395655
Hydralazine and Valproate Added to Chemotherapy for Breast Cancer
A Phase II Clinical Study of Hydralazine and Valproic Acid in Combination With Neoadjuvant Cytotoxic Chemotherapy in Stage IIB and IIIA Breast Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Tlalpan
-
Mexico City, Tlalpan, Mexico, 14080
- Instituto Nacional de Cancerologia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Aged 18 and older; histologically proven invasive T2-3, N0-2, and M0 (stages IIB-IIIA) breast carcinoma; Eastern Cooperative Oncology Group performance status ≤2. Hematological function: Absolute leukocyte count ≥4,000/mm3, platelets ≥100,000/mm3, hemoglobin ≥9.0 g/dL. Hepatic function: total bilirubin, aspartate amino transferase and alanine amino transferase <1.5 the upper normal limit. Renal function: creatinine ≤1.2 mg/dL or a calculated creatinine clearance of ≥60 mL/min. Written informed consent.
Exclusion Criteria:
A history of allergy to sulphas, hydralazine, or magnesium valproate. Past or present condition of rheumatic disease, central nervous system disease, heart failure from aortic stenosis and postural hypotension as diagnosed by a physician. Previous use of the experimental drugs. Pregnancy and breast-feeding. Uncontrolled systemic disease or infection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Global DNA methylation
|
Histone Deacetylase Activity
|
Global gene expression
|
Secondary Outcome Measures
Outcome Measure |
---|
Pathological response
|
Hydralazine plasma levels
|
Valproic acid plasma levels
|
Collaborators and Investigators
Investigators
- Principal Investigator: Claudia Arce, MD, Division of Clinical Research, IInstituto Nacional de Cancerologia, Mexico
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Central Nervous System Depressants
- Enzyme Inhibitors
- Tranquilizing Agents
- Psychotropic Drugs
- GABA Agents
- Anticonvulsants
- Antimanic Agents
- Valproic Acid
- Hydralazine
Other Study ID Numbers
- 005/012/ICI
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced Breast Cancer
-
Introgen TherapeuticsCompletedLocally Advanced Breast Cancer (LABC)United States
-
Abramson Cancer Center at Penn MedicineActive, not recruitingAdvanced Breast Cancer | Metastatic Breast Cancer | BRCA1 Mutation | BRCA2 Mutation | Locally Advanced Breast CancerUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingBreast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Breast Cancer Stage IV | Locally Advanced Breast Cancer | Metastatic Triple-Negative Breast Carcinoma | Locally Advanced Triple-Negative Breast CarcinomaUnited States
-
Icahn School of Medicine at Mount SinaiTerminatedLocally Advanced Breast CancerUnited States
-
Novartis PharmaceuticalsCompletedLocally Advanced Breast CancerBrazil
-
Spanish Breast Cancer Research GroupAstraZenecaRecruitingMetastatic Breast Cancer | Locally Advanced Breast CancerSpain
-
Imperial College LondonCancer Research UKCompletedMetastatic Breast Cancer | Locally Advanced Breast CancerUnited Kingdom
-
Hospices Civils de LyonNot yet recruiting
-
RenJi HospitalRecruitingLocally Advanced Breast CancerChina
-
Memorial Sloan Kettering Cancer CenterRecruitingBreast Cancer | Locally Advanced Breast CancerUnited States
Clinical Trials on Hydralazine and magnesium valproate administration
-
National Institute of CancerologíaNational Council of Science and Technology, Mexico; Psicofarma S.A. de C.V.CompletedRefractory Solid TumorsMexico
-
National Institute of CancerologíaUnknown
-
National Institute of CancerologíaPsicofarma S.A. de C.V.Unknown
-
National Institute of CancerologíaNational Council of Science and Technology, Mexico; Psicofarma S.A. de C.V.Completed
-
New Mexico Cancer Care AllianceCompleted
-
National Institute of CancerologíaPsicofarma S.A. de C.V.UnknownCervical CancerMexico
-
Brigham and Women's HospitalCompletedChronic Hemodialysis (ESRD)United States
-
Shahid Sadoughi University of Medical Sciences...McMaster University; National Institute for Medical Research Development (NIMAD)Recruiting
-
Kaohsiung Veterans General Hospital.E-DA HospitalRecruitingMitral Regurgitation | Systolic Heart Failure Stage D (Disorder)Taiwan
-
University of ArkansasWithdrawnRectal Cancer